Lin Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lin Zheng has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jingyi Tan
School of Pharmacy, Guangdong Medical University, Zhanjiang 524023, China
1 shared publication - Minhua Wu
School of basic medicine, Guangdong medical university, Zhanjiang, China
1 shared publication - Panfeng He
The First Clinical Medical College, Guangdong Medical University, Zhanjiang 524023, China
1 shared publication - Shen Wang
School of Pharmacy, Guangdong Medical University, Zhanjiang 524023, China
1 shared publication - Xiaoxia Ye
School of Basic Medical Sciences, Guangdong Medical University, Zhanjiang, Guangdong 524023, China; Pathological Diagnosis and Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524023, China
1 shared publication - Yanmin Feng
The First Clinical Medical College, Guangdong Medical University, Zhanjiang 524023, China
1 shared publication
Latest Publications
- Open Access
Rosavin: Research Advances in Extraction and Synthesis, Pharmacological Activities and Therapeutic Effects on Diseases of the Characteristic Active Ingredients of Rhodiola rosea L.
Rhodiola rosea L. (RRL) is a popular plant in traditional medicine, and Rosavin, a characteristic ingredient of RRL, is considered one of the most important active ingredients in it. In recent years, with deepening research on its pharmacological actions, the clinical application value and demand for Rosavin have been steadily increasing. Various routes for the extraction and all-chemical or biological synthesis of Rosavin have been gradually developed for the large-scale production and broad application of Rosavin. Pharmacological studies have demonstrated that Rosavin has a variety of biological activities, including antioxidant, lipid-lowering, analgesic, antiradiation, antitumor and immunomodulation effects. Rosavin showed significant therapeutic effects on a range of chronic diseases, including neurological, digestive, respiratory and bone-related disorders during in vitro and vivo experiments, demonstrating the great potential of Rosavin as a therapeutic drug for diseases. This paper gives a comprehensive and insightful overview of Rosavin, focusing on its extraction and synthesis, pharmacological activities, progress in disease-treatment research and formulation studies, providing a reference for the production and preparation, further clinical research and applications of Rosavin in the future.
Open AccessRosavin: Research Advances in Extraction and Synthesis, Pharmacological Activities and Therapeutic Effects on Diseases of the Characteristic Active Ingredients of Rhodiola rosea L.
Rhodiola rosea L. (RRL) is a popular plant in traditional medicine, and Rosavin, a characteristic ingredient of RRL, is considered one of the most important active ingredients in it. In recent years, with deepening research on its pharmacological actions, the clinical application value and demand for Rosavin have been steadily increasing. Various routes for the extraction and all-chemical or biological synthesis of Rosavin have been gradually developed for the large-scale production and broad application of Rosavin. Pharmacological studies have demonstrated that Rosavin has a variety of biological activities, including antioxidant, lipid-lowering, analgesic, antiradiation, antitumor and immunomodulation effects. Rosavin showed significant therapeutic effects on a range of chronic diseases, including neurological, digestive, respiratory and bone-related disorders during in vitro and vivo experiments, demonstrating the great potential of Rosavin as a therapeutic drug for diseases. This paper gives a comprehensive and insightful overview of Rosavin, focusing on its extraction and synthesis, pharmacological activities, progress in disease-treatment research and formulation studies, providing a reference for the production and preparation, further clinical research and applications of Rosavin in the future.